Home>Topics>Authors>Matthew Coffina

Matthew Coffina

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Any Current Thoughts on HCP?

    Commentary

    Thu, 7 Aug 2014

    I have some bond maturities shortly. Matthew Coffina says, "HCP is the closest thing we own to a bond, yet I would choose this leading health-care REIT over a fixed income security any day." The current yield is 5.21%. Any thoughts?

  2. Our Outlook for the Stock Market

    Headlines

    Wed, 25 Sep 2013

    using fundamental research to identify great companies trading at a discount. As Morningstar Stock Investor Editor Matthew Coffina , CFA put it , "I remain focused on a singular goal: seeking out companies with strong and growing competitive advantages

  3. Coffina: Stocks Still Best Vehicle for Long-Run Wealth

    Video Reports

    Thu, 22 Aug 2013

    of those factors are, and also his expectations for returns going forward. Matt, thanks for joining me today. Matthew Coffina : Thanks for having me, Jeremy. Glaser: Benjamin Graham famously said in the short term the market is a voting

    Matthew Coffina found at 0:18

    his expectations for returns going forward. Matt, thanks for joining me today. Matthew Coffina : Thanks for having me, Jeremy. Glaser: Benjamin Graham famously said in the short term the market is a voting machine, but in
  4. How Morningstar Values Stocks

    Video Reports

    Thu, 25 Apr 2013

    editor of StockInvestor , and he previously was the valuation model developer. Matt, thanks for joining me today. Matthew Coffina : Thanks for having me, Jeremy. Glaser: Let's start at the beginning. What kind of model do our analysts use

    Matthew Coffina found at 0:19

    previously was the valuation model developer. Matt, thanks for joining me today. Matthew Coffina : Thanks for having me, Jeremy. Glaser: Let's start at the beginning. What kind of model do our analysts use to come up
  5. Top Picks From Morningstar's Strategists

    Video Reports

    Wed, 3 Apr 2013

    adding to MLPs, master limited partnerships, with the time horizon of forever? Do those stocks look attractive? Matthew Coffina : Well, I think that there is relatively few opportunities among MLPs right now. Two names that I do like, [TICKER

    Matthew Coffina found at 5:11

    partnerships, with the time horizon of forever? Do those stocks look attractive? Matthew Coffina : Well, I think that there is relatively few opportunities among MLPs right now. Two names that I do like, [TICKER:ETE] Energy Transfer Equity.
  6. Mystery Bidder Tops Bristol's Imclone Bud

    Commentary

    Wed, 10 Sep 2008

    Millennium Pharmaceuticals and also recently discontinued development of its own EGFR antibody (a similar drug to Imclone's Erbitux), would be a likely outside bidder. Morningstar equity analyst Matthew Coffina also contributed to this note.

  7. Bristol Makes Offer for Imclone

    Commentary

    Thu, 31 Jul 2008

    Erbitux salesforces in the United States, but it also stems from Bristol's understanding of Imclone's pipeline potential--factors that aren't likely to be duplicated in an outside bid. Matthew Coffina contributed to this note.

Content Partners